U.S. Anemia Treatment Market Research Report Forecast: (2025-2030)

Market Definition

Anemia treatment must be conscious of addressing the underlying causes, inclusive of iron deficiency, vitamin deficiency, folate deficiency, persistent illnesses, or blood loss. Treatment alternatives might also involve iron supplements, vitamin supplements, erythropoiesis-stimulating sellers, blood transfusions, and, in certain cases, gene remedies.

Market Insights & Analysis: U.S. Anemia Treatment Market (2025-30):

The U.S. Anemia Treatment Market size was valued at around USD 1.07 billion in 2024 and is projected to reach USD 1.98 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 10.14% during the forecast period, i.e., 2025-30. The U.S. Anemia Treatment Market has substantial growth as a result of multiple factors such as accidents and increased surgical treatments, resulting in a growing incidence rate of blood disorders. This can be seen in iron deficiency, which is the most common reason behind anemia. For instance, the number of anemia diagnoses has been increasing due to the rise in the aging population, especially among elderly people, who might have a higher risk of chronic diseases, such as kidney disease and cancer. Both of these conditions have higher chances of anemia.

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

However, the rising number of accidents and surgeries raises the need for anemia treatment. For instance, as per the National Trauma Institute, around 2 million people are treated with traumatic injuries annually in the U.S. Such injuries lead to a huge amount of blood loss and require immediate medical attention to control anemia. Due to the increased chance of getting anemia cases as a result of surgeries involving loss or post-surgical complications, replacement surgery at the joint and heart-related surgeries lead to blood-related complications. Hence, hospital and emergency care are growing to present better treatment solutions for anemia. As the demand for better anemia management continues to grow, pharmaceutical companies have started with innovative therapies that provide better and more convenient treatment options for patients, and expanding the market.

For instance, the U. S. Food and Drug Administration is consistently approving new drugs and treatments for anemia. Recently, it approved Jesduvroq tablets (daprodustat) for the oral treatment of anemia related to chronic kidney disease in adult patients who have been undergoing dialysis for a minimum of four months. This emphasis on R&D is advancing the creation of more personalized anemia treatments, including oral iron supplements with improved absorption, intravenous iron therapies, and innovative biologics such as erythropoiesis-stimulating agents (ESAs). Consequently, the U. S. anemia treatment industry is poised for substantial growth in the coming years, as ongoing R&D investments will facilitate enhanced solutions for patients and healthcare providers.

U.S. Anemia Treatment Market Driver:

Growing Prevalence of Chronic Diseases in the United States – In the U.S., the growing incidence of chronic disease is drastically influencing the dynamics of the Anemia industry. These ailments cause the body to supply insufficient quantities of healthy red blood cells which ends up in anemia. As per the National Institute of Diabetes and Digestive and Kidney Diseases, around 15% of U.S. Adults, which is nearly 37 million, have chronic kidney disorder (CKD). Similarly, chemotherapy is a shape of most cancer treatments that regularly disrupt because of red blood cells, therefore causing anemia. According to the American Cancer Society, almost 1.9 million new cancer cases are diagnosed every year in the U.S., many requiring supportive anemia healing procedures for fatigue management. To meet this demand, erythropoiesis-stimulating agents (ESAs) are notably used to set off crimson blood cell manufacturing amongst patients stricken by CKD or whoever undergoing cancer remedy.

The U.S. healthcare system is witnessing increased use of advanced iron therapies and other anemia management solutions. These developments coupled with the growing healthcare spending and innovation in anemia treatment make the U.S. market a leader in treating anemia caused by chronic disease.

U.S. Anemia Treatment Market Opportunity:

Awareness Campaigns and Health Education – The awareness campaign has smooth routine screenings, resulting in a rise in diagnosed cases. As per the NIH, in 2023 iron deficiency anemia is the most prevalent type in the U. S., and affects around 5 million individuals per year. It is the leading cause of anemia both in the United States and around the world. In American men, around 5% to 11% are iron deficient, while for women, the figure reaches from 1% to 4%. In children, the rates surpass 5% and 2%, respectively. A major cause of iron deficiency anemia (IDA) is a lack of iron intake or absorption, which is unusually common among women and children. This increased awareness has also led to a greater demand for costly treatments, thereby creating profitable opportunities for pharmaceutical companies to introduce new treatments and expand their market presence.

Therefore, awareness campaigns and health education are increasing the demand for anemia treatment in the U.S. Government agencies like the CDC have important roles in creating awareness among the masses about anemia and its results on their health. For instance, The CDC Iron Deficiency Anemia Prevention and Control program educates consumers and healthcare providers about early diagnosis and treatment methods, especially in high-risk populations like children, pregnant women, and the elderly.

U.S. Anemia Treatment Market Challenge:

High Cost of Advanced Anemia Treatment – The high cost of advanced anemia treatment in the U.S. makes it hard for many sufferers to have enough money for them. The new treatment plans, including gene-based remedies and advanced biologics, are very powerful and expensive. For example, as in line with Medicare records erythropoiesis-stimulating dealers, which might be frequently used to deal with anemia in chronic kidney ailment, can cost more than USD 10,000 in line with an affected person every 12 months. This value is especially high for those who no longer have insurance or have minimum insurance due to the fact they may keep away from the remedies because of unaffordability. As in line with the Kaiser family basis, about 10% of American citizens no longer have health insurance, and this makes it even harder for them to receive those essential remedies.

U.S. Anemia Treatment Market Trend:

Technological Advancements Transforming Anemia Management – The U.S. Anemia Treatment market is going through significant changes in terms of transformation due to the latest advancements in the field of diagnosis and treatment. Innovative tools such as AI-enabled diagnostic systems and advanced intravenous iron remedies improve the efficiency and accuracy of anemia management. The use of AI permits fitness professionals to examine blood assessments to pick out anemia-related deficiencies with a great deal more precision than before analysis, thereby presenting the opportunity for advanced and extra-powerful interventions.

Moreover, oral iron supplements with progressed absorption and gene-based remedies offer better compliance and fewer aspect outcomes for patients. For instance, as per the U.S. Centers for Medicare & Medicaid offerings, healthcare spending within the United States will attain more than USD 6 trillion, with a massive chunk of that going toward persistent ailment management. These technological advancements no longer simply improve results but additionally cater to the growing demand for affected person-targeted remedies.

U.S. Anemia Treatment Market (2025-30): Segmentation Analysis

The U.S. Anemia Treatment Market study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2025–2030 at the national level. Based on the analysis, the market has been further classified as:

Based on Disease Type:

• Iron Deficiency Anemia
• Sickle Cell Anemia
• Aplastic Anemia
• Vitamin Deficiency Anemia

Based on disease type, vitamin deficiency Anemia, the most common form of Macrocytic Anemia (High MCV), has the largest market share of around 30% in the U.S. This condition is widespread, often resulting from a deficiency in essential vitamins such as folate or vitamin B12. Additionally, inadequate diets, older adults, and individuals with certain medical conditions that affect nutrient absorption commonly experience this issue. The treatment for vitamin deficiency anemia is generally uncomplicated, with oral supplements being the most commonly used option. These are preferred due to their cost-effectiveness and ease of administration, and they effectively restore nutrient levels. Dietary changes can also address this type of anemia, which continues to represent the largest segment in the anemia treatment market.

Based on Drug:

• Bone Marrow Stimulants
• Gene Therapy
• Corticosteroids
• Iron Chelating Agents
• Supplements

Dietary supplements have the most important marketplace proportion around 40%. This consists of oral and intravenous iron dietary supplements, which are the maximum common and widely used remedies for situations such as Iron Deficiency Anemia and vitamin deficiency anemia. Iron dietary supplements are easily handy, value-powerful, and widely prescribed due to their confirmed efficacy in treating anemia due to iron deficiencies. These dietary supplements are generally used throughout a spread of patient demographics, particularly among girls of youngster’s pregnant girls, and those with continual blood loss.

U.S. Anemia Treatment Market (2025-30): Regional Projections

Geographically, U.S. Anemia Treatment Market expands across:

• North
• East
• Mid-West
• South

In the U.S. Anemia Treatment Market, the South region has the largest market proportion around 40%. This is mainly because of the higher occurrence of anemia in the South, which is mainly pushed through nutritional deficiencies, and chronic sicknesses. A higher prevalence of chronic diseases such as diabetes can increase the demand for disease treatment, thus augmenting the size & volume of the Anemia Treatment Industry in this specific region compared to other regions. As per the Centre for Disease Control and Prevention, anemia is highly preventive in the Southern States, as a result, the Government Authority is taking significant initiatives towards healthcare accessibility, which ultimately helps the growth & expansion of the market in the southern region of the United States.

U.S. Anemia Treatment Industry Recent Development:

• September 2024: Pfizer Inc. announced that it voluntarily withdrew all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) in all approved markets. Additionally, Pfizer discontinued all active voxelotor clinical trials and expanded access programs worldwide.

Gain a Competitive Edge with Our U.S. Anemia Treatment Market Report

1. U.S. Anemia Treatment Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
2. This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
3. U.S. Anemia Treatment Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.